The Center for Biosimilars® recaps the top stories for the week of July 22, 2019.
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 22, 2019.
Number 5: Sandoz announced that it has enrolled its first patient in a study of a proposed biosimilar, GP2411.
Number 4: The European Medicines Agency will review Samsung Bioepis’ proposed biosimilar, SB8.
Number 3: A new paper argues that regulators should affirm the interchangeability of approved biosimilars.
Number 2: The FDA approved its fourth adalimumab biosimilar on Tuesday.
Number 1: Also on Tuesday, the FDA approved its second rituximab biosimilar.
Finally, last week, our e-newsletter asked whether you think that advocacy groups will play a role in US biosimilar uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.